Proteogenomic Characterization of Endometrial Carcinoma

the Clinical Proteomic Tumor Analysis Consortium

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

We undertook a comprehensive proteogenomic characterization of 95 prospectively collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This analysis revealed possible new consequences of perturbations to the p53 and Wnt/β-catenin pathways, identified a potential role for circRNAs in the epithelial-mesenchymal transition, and provided new information about proteomic markers of clinical and genomic tumor subgroups, including relationships to known druggable pathways. An extensive genome-wide acetylation survey yielded insights into regulatory mechanisms linking Wnt signaling and histone acetylation. We also characterized aspects of the tumor immune landscape, including immunogenic alterations, neoantigens, common cancer/testis antigens, and the immune microenvironment, all of which can inform immunotherapy decisions. Collectively, our multi-omic analyses provide a valuable resource for researchers and clinicians, identify new molecular associations of potential mechanistic significance in the development of endometrial cancers, and suggest novel approaches for identifying potential therapeutic targets.

Original languageEnglish
Pages (from-to)729-748.e26
JournalCell
Volume180
Issue number4
DOIs
StatePublished - Feb 20 2020

Keywords

  • CTNNB1
  • TP53
  • acetylation
  • circular RNA
  • endometrial cancer
  • endometrioid endometrial cancer
  • immune evasion
  • proteogenomics
  • proteomics
  • serous endometrial cancer

Fingerprint Dive into the research topics of 'Proteogenomic Characterization of Endometrial Carcinoma'. Together they form a unique fingerprint.

  • Cite this

    the Clinical Proteomic Tumor Analysis Consortium (2020). Proteogenomic Characterization of Endometrial Carcinoma. Cell, 180(4), 729-748.e26. https://doi.org/10.1016/j.cell.2020.01.026